Trial Information
Multimodality Functional Imaging (MRS and Tumor Perfusion) Predicts Tumor Migration, Invasiveness, and Patterns of Failure of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide
Inclusion Criteria:
- Histologically confirmed glioblastoma multiforme
- Ages 18-65
- Karnofsky Performance Scale (KPS) equal to or less than 70
- Minimal neurological deficit
- Eligible for concurrent temozolomide chemotherapy
Exclusion Criteria:
- Prior radiation therapy to hand or neck area, chemotherapy, or radiosensitizer
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
determine tumor response and pattern of failure using functional MRI imaging
Outcome Time Frame:
Study completion
Principal Investigator
Bassam Abdulkarim, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Alberta Health Services
Authority:
Canada: Health Canada
Study ID:
CNS-09-0027 / ethics 21780
NCT ID:
NCT00250211
Start Date:
March 2005
Completion Date:
April 2011
Related Keywords:
- Glioblastoma
- Glioma
- magnetic resonance imaging, functional
- radiation therapy
- temozolomide
- functional imaging
- concurrent chemoradiation
- Glioblastoma
- Glioma
